Modulation of redox system such as inhibition of GSH synthesis and regeneration or NRF2 pathway inhibition could therefore represent appealing new therapeutic strategies to overcome melphalan resistance in multiple myeloma. The gene discussed is NFE2L2; the disease is plasma cell myeloma.